635702-24-8

Usage

Uses

Used in Pharmaceutical Industry:
(4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol is used as a potential pharmaceutical compound for its possible biological and pharmacological properties. The presence of multiple functional groups may contribute to its efficacy in various therapeutic applications, although further research is needed to confirm its specific uses and mechanisms of action.
Used in Chemical Research:
In the field of chemical research, (4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol serves as a subject for study to understand its chemical properties, reactivity, and potential interactions with other molecules. This research could lead to the development of new compounds with specific applications in various industries.
Used in Material Science:
(4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol may be utilized in material science for the development of new materials with unique properties. (4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol's structure and functional groups could contribute to the creation of materials with specific characteristics, such as improved stability, reactivity, or selectivity in certain applications.

Upstream product

• 635702-23-7 (E)-N′-hydroxy-4-(hydroxymethyl)benzimidamide 
• 38861-88-0 4-isobutylbenzoic acid 
• 635702-23-7 N-hydroxy-4-(hydroxymethyl)benzenecarboximidamide 
• 2592-95-2 benzotriazol-1-ol 
• 1233243-49-6 (Z)-N'-hydroxy-4-(hydroxymethyl)benzimidamide 
• 874-89-5 4-Cyanobenzyl alcohol 

Downstream Products

• 635701-88-1 4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzaldehyde 
• 635701-59-6 1-{4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl}-3-azetidine carboxylic acid 

Relevant academic research and scientific papers

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

CYCLOALKYLAMINO ACID DERIVATIVES

The invention relates to compounds of formula I and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof; wherein B, D, E, R1, R2, R3, R4, R5, R8, m, n, p, q, r, s, t and u are as defined herein. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF

Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocylcic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, in which when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt thereof; an N-oxide form thereof; a solvate thereof; a prodrug thereof; and a medicament which includes those. The compound represented by formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.

AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF

A compound represented by the general formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug of any of these; and a drug containing any of these. (I) (In the formula, all the symbols are as defined in the description.) The compound represented by the general formula (I) has the ability to combine with an S1P receptor (especially EDG-1, EDG-6, and/or EDG-8). It is useful for the prevention and/or treatment of rejection reactions to transplantation, graft versus host diseases, autoimmune diseases, allergic diseases, neurodegenerative diseases, etc.

Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3

A class of 3,5-diphenyl-1,2,4-oxadiazole based compounds have been identified as potent sphingosine-1-phosphate-1 (S1P1) receptor agonists with minimal affinity for the S1P2 and S1P3 receptor subtypes. Analogue 26 (S1P1 IC50 = 0.6 nM) has an excellent pharmacokinetics profile in the rat and dog and is efficacious in a rat skin transplant model, indicating that S1P3 receptor agonism is not a component of immunosuppressive efficacy.

PROCESS FOR MAKING AZETIDINE-3-CARBOXYLIC ACID

The present invention is directed to an improved process for synthesizing azetidine-3-carboxylic acid, comprising triflating diethylbis(hydroxymethyl)malonate followed by azetidine ring-formation by intramolecular cyclization using an amine, decarboxylation to give the mono acid azetidine and hydrogenation to give the title compound. Azetidine-3-carboxylic acid is useful as an intermediate for making certain S1P?1#191/Edg1 receptor agonists, which are immunosupressive agents.

1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS

The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.